Finding 1078603 (2020-006)

Significant Deficiency Repeat Finding
Requirement
M
Questioned Costs
-
Year
2020
Accepted
2024-10-10

AI Summary

  • Core Issue: AAPT did not document risk assessments for subrecipients, violating federal requirements for monitoring compliance.
  • Impacted Requirements: Failure to follow 2 CFR 200.331(b) could lead to oversight gaps with high-risk subrecipients.
  • Recommended Follow-Up: AAPT should adhere to internal policies, document risk assessments, and implement a risk scaling system for oversight procedures.

Finding Text

Finding 2020-006: Subrecipient Monitoring Federal Program: Research and Development Cluster (Education and Human Resources) Assistance Listing Number and Title: 47.076 STEM Education Name of Federal Agency, Pass Through Entity (when applicable), Award Number and Year: National Science Foundation: 1640791 (9/15/2016 – 8/31/2022) Significant Deficiency in Internal Controls Over Compliance, Other matters Criteria or Specific Requirement (Including Statutory, Regulatory, or Other Citation): As stated in 2 CFR 200.331 part (b), all pass-through entities must evaluate each subrecipient's risk of noncompliance with Federal statutes, regulations, and the terms and conditions of the subaward for purposes of determining the appropriate subrecipient monitoring procedures to prescribe to each individual subrecipient. Condition: During our audit work over subrecipient monitoring, we were unable to verify that pre-award risk assessment procedures were performed. It is our understanding that AAPT has ongoing relationships with these subrecipients and evaluation of these subrecipients' risk is a continual process; however, these procedures were not documented. Cause: AAPT’s internal policies and procedures governing risk assessment on subrecipient was not performed. Effect or Potential Effect: AAPT could inadvertently engage in relationships with subrecipients of higher risk without the appropriate level of oversight to ensure subrecipients are expending funds in accordance with the provisions and terms of the subaward. Questioned Costs: None noted. Context: Our audit procedures consisted of examining documentation of the subrecipient monitoring process, and evaluating internal controls over the process. Identification as a Repeat Finding, if Applicable: 2019-005. Recommendation: We recommend AAPT follow their internal policies and procedures surrounding subrecipients and document the risk assessment criteria for the purpose of determining the expected level of oversight during the period of performance. This evaluation should include a scaling system, such as high, medium or low risk (for example), and the monitoring tools and procedures to be performed at each of these levels (additional training, on-site reviews, types of and frequency of reporting, etc.). Views of Responsible Officials and Planned Corrective Actions: Management will continue to perform risk assessment procedures and will thoroughly document the processes and evaluations. Anticipated Completion Date: 12/31/2022 Responsible Official: Michael Brosnan, CFO

Categories

Subrecipient Monitoring Period of Performance

Other Findings in this Audit

  • 502144 2020-001
    Significant Deficiency
  • 502145 2020-002
    Material Weakness Repeat
  • 502146 2020-005
    Significant Deficiency Repeat
  • 502147 2020-001
    Significant Deficiency
  • 502148 2020-002
    Material Weakness Repeat
  • 502149 2020-005
    Significant Deficiency Repeat
  • 502150 2020-001
    Significant Deficiency
  • 502151 2020-002
    Material Weakness Repeat
  • 502152 2020-004
    Significant Deficiency
  • 502153 2020-005
    Significant Deficiency Repeat
  • 502154 2020-001
    Significant Deficiency
  • 502155 2020-002
    Material Weakness Repeat
  • 502156 2020-004
    Significant Deficiency
  • 502157 2020-005
    Significant Deficiency Repeat
  • 502158 2020-001
    Significant Deficiency
  • 502159 2020-002
    Material Weakness Repeat
  • 502160 2020-005
    Significant Deficiency Repeat
  • 502161 2020-006
    Significant Deficiency Repeat
  • 502162 2020-001
    Significant Deficiency
  • 502163 2020-002
    Material Weakness Repeat
  • 502164 2020-005
    Significant Deficiency Repeat
  • 502165 2020-001
    Significant Deficiency
  • 502166 2020-002
    Material Weakness Repeat
  • 502167 2020-004
    Significant Deficiency
  • 502168 2020-005
    Significant Deficiency Repeat
  • 502169 2020-001
    Significant Deficiency
  • 502170 2020-002
    Material Weakness Repeat
  • 502171 2020-005
    Significant Deficiency Repeat
  • 502172 2020-001
    Significant Deficiency
  • 502173 2020-002
    Material Weakness Repeat
  • 502174 2020-005
    Significant Deficiency Repeat
  • 502175 2020-001
    Significant Deficiency
  • 502176 2020-002
    Material Weakness Repeat
  • 502177 2020-003
    Material Weakness Repeat
  • 502178 2020-005
    Significant Deficiency Repeat
  • 502179 2020-001
    Significant Deficiency
  • 502180 2020-002
    Material Weakness Repeat
  • 502181 2020-003
    Material Weakness Repeat
  • 502182 2020-005
    Significant Deficiency Repeat
  • 502183 2020-001
    Significant Deficiency
  • 502184 2020-002
    Material Weakness Repeat
  • 502185 2020-005
    Significant Deficiency Repeat
  • 502186 2020-001
    Significant Deficiency
  • 502187 2020-002
    Material Weakness Repeat
  • 502188 2020-005
    Significant Deficiency Repeat
  • 502189 2020-001
    Significant Deficiency
  • 502190 2020-002
    Material Weakness Repeat
  • 502191 2020-005
    Significant Deficiency Repeat
  • 502192 2020-001
    Significant Deficiency
  • 502193 2020-002
    Material Weakness Repeat
  • 502194 2020-005
    Significant Deficiency Repeat
  • 502195 2020-001
    Significant Deficiency
  • 502196 2020-002
    Material Weakness Repeat
  • 502197 2020-005
    Significant Deficiency Repeat
  • 502198 2020-001
    Significant Deficiency
  • 502199 2020-002
    Material Weakness Repeat
  • 502200 2020-005
    Significant Deficiency Repeat
  • 502201 2020-001
    Significant Deficiency
  • 502202 2020-002
    Material Weakness Repeat
  • 502203 2020-005
    Significant Deficiency Repeat
  • 1078586 2020-001
    Significant Deficiency
  • 1078587 2020-002
    Material Weakness Repeat
  • 1078588 2020-005
    Significant Deficiency Repeat
  • 1078589 2020-001
    Significant Deficiency
  • 1078590 2020-002
    Material Weakness Repeat
  • 1078591 2020-005
    Significant Deficiency Repeat
  • 1078592 2020-001
    Significant Deficiency
  • 1078593 2020-002
    Material Weakness Repeat
  • 1078594 2020-004
    Significant Deficiency
  • 1078595 2020-005
    Significant Deficiency Repeat
  • 1078596 2020-001
    Significant Deficiency
  • 1078597 2020-002
    Material Weakness Repeat
  • 1078598 2020-004
    Significant Deficiency
  • 1078599 2020-005
    Significant Deficiency Repeat
  • 1078600 2020-001
    Significant Deficiency
  • 1078601 2020-002
    Material Weakness Repeat
  • 1078602 2020-005
    Significant Deficiency Repeat
  • 1078604 2020-001
    Significant Deficiency
  • 1078605 2020-002
    Material Weakness Repeat
  • 1078606 2020-005
    Significant Deficiency Repeat
  • 1078607 2020-001
    Significant Deficiency
  • 1078608 2020-002
    Material Weakness Repeat
  • 1078609 2020-004
    Significant Deficiency
  • 1078610 2020-005
    Significant Deficiency Repeat
  • 1078611 2020-001
    Significant Deficiency
  • 1078612 2020-002
    Material Weakness Repeat
  • 1078613 2020-005
    Significant Deficiency Repeat
  • 1078614 2020-001
    Significant Deficiency
  • 1078615 2020-002
    Material Weakness Repeat
  • 1078616 2020-005
    Significant Deficiency Repeat
  • 1078617 2020-001
    Significant Deficiency
  • 1078618 2020-002
    Material Weakness Repeat
  • 1078619 2020-003
    Material Weakness Repeat
  • 1078620 2020-005
    Significant Deficiency Repeat
  • 1078621 2020-001
    Significant Deficiency
  • 1078622 2020-002
    Material Weakness Repeat
  • 1078623 2020-003
    Material Weakness Repeat
  • 1078624 2020-005
    Significant Deficiency Repeat
  • 1078625 2020-001
    Significant Deficiency
  • 1078626 2020-002
    Material Weakness Repeat
  • 1078627 2020-005
    Significant Deficiency Repeat
  • 1078628 2020-001
    Significant Deficiency
  • 1078629 2020-002
    Material Weakness Repeat
  • 1078630 2020-005
    Significant Deficiency Repeat
  • 1078631 2020-001
    Significant Deficiency
  • 1078632 2020-002
    Material Weakness Repeat
  • 1078633 2020-005
    Significant Deficiency Repeat
  • 1078634 2020-001
    Significant Deficiency
  • 1078635 2020-002
    Material Weakness Repeat
  • 1078636 2020-005
    Significant Deficiency Repeat
  • 1078637 2020-001
    Significant Deficiency
  • 1078638 2020-002
    Material Weakness Repeat
  • 1078639 2020-005
    Significant Deficiency Repeat
  • 1078640 2020-001
    Significant Deficiency
  • 1078641 2020-002
    Material Weakness Repeat
  • 1078642 2020-005
    Significant Deficiency Repeat
  • 1078643 2020-001
    Significant Deficiency
  • 1078644 2020-002
    Material Weakness Repeat
  • 1078645 2020-005
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
47.049 Mathematical and Physical Sciences $10,562
47.076 Education and Human Resources $6,442
43.001 Science $4,172